| Soluble receptor isoform of IFN-beta (sIFNAR2) in multiple sclerosis patients and their association with the clinical response to IFN-beta treatment P Aliaga-Gaspar, I Hurtado-Guerrero, NL Ciano-Petersen, P Urbaneja, ... Frontiers in Immunology 12, 778204, 2021 | 9 | 2021 |
| Antiviral, immunomodulatory and antiproliferative activities of recombinant soluble IFNAR2 without IFN-ss mediation I Hurtado-Guerrero, B Hernáez, MJ Pinto-Medel, E Calonge, ... Journal of Clinical Medicine 9 (4), 959, 2020 | 9 | 2020 |
| Natalizumab-immunogenicity evaluation in patients with infusion related events or disease exacerbations NL Ciano-Petersen, P Aliaga-Gaspar, I Hurtado-Guerrero, V Reyes, ... Frontiers in Immunology 14, 1242508, 2023 | 2 | 2023 |
| Recombinant soluble type I interferon receptor exerts antiviral activity by inducing proteins related to autophagy P Aliaga-Gaspar, I Brichette-Mieg, MM Fernández-Arjona, ... Biomedicine & Pharmacotherapy 181, 117678, 2024 | | 2024 |
| Oxidative Stress and Symptoms Associated with Multiple Sclerosis. R Piñar-Morales, R Duran-Ogalla, A Bautista, MJ Garcia, P Aliaga-Gaspar, ... | | 2024 |
| Differences in alternatively spliced RNA isoforms in blood of multiple sclerosis patiens I Brichette Mieg, AM Alonso Torres, J Luis Rodriguez-Bada, ... MULTIPLE SCLEROSIS JOURNAL 29, 312-313, 2023 | | 2023 |
| Analysis of serum protein biomarkers in clinical forms of Multiple Sclerosis I Brichette-Mieg, P Aliaga-Gaspar, J Rodríguez-Bada, A Alonso-Torres, ... | | |
